Zhitong Finance APP was informed that Xiaomo released a research report stating that after the release of the third quarter performance of the 3 quarters of the heart pulse medical (688016.SH) affiliated heartbroken medical treatment (00853)The target price of H shares rose from HK $ 7.5 to HK $ 7.8, and the rating "increased its holdings".The thoracic/abdominal aortic brackets of the aortic stent business department are reduced by about 40%at the end user level, and 20%to 35%. It is expected that the heart pulse medical treatment will bear most of the impact, which will be converted to its factory price by 25%to 25%to the factory price.30%.
However, the banks efforts to improve the efficiency of the heart pulse medical treatment will help long -term profit margins, and the long -term net profit margin forecast is greatly raised from 23%to about 30%.Therefore, the bank also raised the long -term net profit margin forecast of minimally invasive care, and it was revised up to 12%from the original 11%.The bank maintains that minimally invasive medical care can achieve the main business targets from 2024 to 2026.The bank mentioned that management promised to narrow the losses this year and next, and it is expected to turn losses to earn $ 90 million in 2026.
This article comes from: Zhitong Finance Network
